166 related articles for article (PubMed ID: 36704127)
1. Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation.
Cheyssac E; Savadogo H; Lagoutte N; Baudouin V; Charbit M; Novo R; Sellier-Leclerc AL; Fila M; Decramer S; Merieau E; Zaloszyc A; Harambat J; Roussey G
Front Pediatr; 2022; 10():1085101. PubMed ID: 36704127
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
4. Persistent Epstein-Barr viral load in Epstein-Barr viral naïve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease.
Das B; Morrow R; Huang R; Fixler D
World J Transplant; 2016 Dec; 6(4):729-735. PubMed ID: 28058224
[TBL] [Abstract][Full Text] [Related]
5. (Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation.
Höcker B; Böhm S; Fickenscher H; Küsters U; Schnitzler P; Pohl M; John U; Kemper MJ; Fehrenbach H; Wigger M; Holder M; Schröder M; Feneberg R; Köpf-Shakib S; Tönshoff B
Transpl Int; 2012 Jul; 25(7):723-31. PubMed ID: 22533698
[TBL] [Abstract][Full Text] [Related]
6. Viral load of EBV DNAemia is a predictor of EBV-related post-transplant lymphoproliferative disorders in pediatric renal transplant recipients.
Colombini E; Guzzo I; Morolli F; Longo G; Russo C; Lombardi A; Merli P; Barzon L; Murer L; Piga S; Ciofi Degli Atti ML; Locatelli F; Dello Strologo L
Pediatr Nephrol; 2017 Aug; 32(8):1433-1442. PubMed ID: 28280938
[TBL] [Abstract][Full Text] [Related]
7. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA
Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314
[TBL] [Abstract][Full Text] [Related]
8. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting chronic high load carriage of Epstein-Barr virus is more common in young pediatric renal transplant recipients.
Ladfors SW; Lindahl JK; Hansson S; Brandström P; Andersson R; Jertborn M; Lindh M; Woxenius S; Friman V
Pediatr Nephrol; 2020 Mar; 35(3):427-439. PubMed ID: 31802220
[TBL] [Abstract][Full Text] [Related]
10. Impact of valganciclovir on Epstein-Barr Virus polymerase chain reaction in pediatric liver transplantation: preliminary report.
Venturi C; Bueno J; Gavalda J; Tórtola T; Pou L; Medina A; Codina G; Charco R; Pahissa A
Transplant Proc; 2009 Apr; 41(3):1038-40. PubMed ID: 19376420
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
Quintero Bernabeu J; Juamperez J; Mercadal-Hally M; Larrarte King M; Gallego Melcon S; Gros Subias L; Sábado Álvarez C; Soler-Palacin P; Melendo Pérez S; Esperalba J; Navarro Jiménez A; Garrido Pontnou M; Camacho Soriano J; Hidalgo Llompart E; Bilbao Aguirre I; Charco Torra R
Pediatr Transplant; 2022 Sep; 26(6):e14292. PubMed ID: 35466492
[TBL] [Abstract][Full Text] [Related]
12. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
Front Immunol; 2020; 11():1231. PubMed ID: 32625211
[TBL] [Abstract][Full Text] [Related]
13. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia.
Hyun H; Park E; Cho M; Min SI; Ha J; Kang HJ; Shin HY; Ha IS; Cheong HI; Ahn YH; Kang HG
J Korean Med Sci; 2019 Aug; 34(30):e203. PubMed ID: 31373185
[TBL] [Abstract][Full Text] [Related]
14. Clinical and virologic outcomes in high-risk adult Epstein-Barr virus mismatched organ transplant recipients.
Kumar D; Patil N; Husain S; Chaparro C; Bhat M; Kim SJ; Humar A
Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28489256
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients.
Seo E; Kim J; Oh SH; Kim KM; Kim DY; Lee J
Pediatr Transplant; 2020 Jun; 24(4):e13666. PubMed ID: 32067332
[TBL] [Abstract][Full Text] [Related]
16. Valganciclovir prophylaxis delays onset of EBV viremia in high-risk pediatric solid organ transplant recipients.
Albatati S; Sharma A; Haubrich K; Wright A; Gantt S; Blydt-Hansen TD
Pediatr Res; 2020 Apr; 87(5):892-896. PubMed ID: 31377753
[TBL] [Abstract][Full Text] [Related]
17. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study.
Höcker B; Fickenscher H; Delecluse HJ; Böhm S; Küsters U; Schnitzler P; Pohl M; John U; Kemper MJ; Fehrenbach H; Wigger M; Holder M; Schröder M; Billing H; Fichtner A; Feneberg R; Sander A; Köpf-Shakib S; Süsal C; Tönshoff B
Clin Infect Dis; 2013 Jan; 56(1):84-92. PubMed ID: 23042966
[TBL] [Abstract][Full Text] [Related]
19. Impact of antiviral prophylaxis in adults Epstein-Barr Virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study.
Ville S; Imbert-Marcille BM; Coste-Burel M; Garandeau C; Meurette A; Cantarovitch D; Giral M; Hourmant M; Blancho G; Dantal J
Transpl Int; 2018 May; 31(5):484-494. PubMed ID: 29057508
[TBL] [Abstract][Full Text] [Related]
20. Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.
Sen A; Enriquez J; Rao M; Glass M; Balachandran Y; Syed S; Twist CJ; Weinberg K; Boyd SD; Bernstein D; Trickey AW; Gratzinger D; Tan B; Lapasaran MG; Robien MA; Brown M; Armstrong B; Desai D; Mazariegos G; Chin C; Fishbein TM; Venick RS; Tekin A; Zimmermann H; Trappe RU; Anagnostopoulos I; Esquivel CO; Martinez OM; Krams SM
Front Immunol; 2022; 13():994552. PubMed ID: 36304469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
